Recent investigations suggest a role for antioxidants in preventing ID
DM. MDL 29,311 (4,4'-[methylenebis (thio)]bis[2,6-bis(1,1-dimethylethy
l)]-phenol) is an analogue of the antioxidant probucol. Administered a
s a 1% dietary admixture to female nonobese diabetic mice from 4 to 24
wk of age, MDL reduced the prevalence of diabetes from 49 to 4% at 24
wk of age (n = 50-61/group). Discontinuation of treatment at 24 wk of
age did not result in a rapid onset of diabetes. Probucol (1%) did no
t prevent diabetes. Initiating MDL treatment at 4 or 8 wk of age was m
ore effective (19 and 17%, respectively, compared with 60% in control
mice) than initiating treatment at 12 wk of age (30% diabetic; n = 28-
35/group). A lower dose of MDL (0.1%), started at 4 wk of age, decreas
ed the prevalence of diabetes to 36%. Histopathology indicated that MD
L did not prevent insulitis. MDL (0.1%) also was evaluated in combinat
ion with immunosuppressants. Compared with control mice (65% diabetic)
, the combination of MDL and deflazacort was more effective (21% diabe
tic) than either agent alone (39% diabetic for MDL and 59% diabetic fo
r deflazacort), whereas the effectiveness of MDL, cyclosporin, and MDL
plus cyclosporin was similar (39, 38, and 34% diabetic, respectively)
. In another model of IDDM, the multiple-low-dose streptozocin-injecte
d mouse, MDL (1%) also reduced the prevalence of diabetes when adminis
tered beginning 8 wk before streptozocin (55% diabetic vs. 100% of con
trol mice; n = 20-25/group). Probucol (1%) was ineffective. MDL appear
s effective in preventing the onset of disease in two mouse models of
IDDM.